Skip to main content
Frederick Hayden, MD, Infectious Disease, Charlottesville, VA

FrederickG.HaydenMD

Infectious Disease • Charlottesville, VA

Professor Emeritus, Department of Medicine, University of Virginia School of Medicine

Join to view full profile

Dr. Hayden is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hayden's full profile

Already have an account?

  • Office

    345 Crispell Drive, MR-6
    Charlottesville, VA 22908
    Phone+1 434-924-5059

Education & Training

  • University of Rochester
    University of RochesterFellowship, Infectious Disease, 1976 - 1978
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1973 - 1976
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1973

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 1978 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1992

Publications & Presentations

PubMed

Journal Articles

  • A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19  
    Frederick Hayden, MD, The New England Journal of Medicine
  • Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents  
    Frederick Hayden, MD, The New England Journal of Medicine

Authored Content

  • Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory SyndromeOctober 2020

Press Mentions

  • Mixed Bag for Antiviral Favipiravir in Flu
    Mixed Bag for Antiviral Favipiravir in FluMay 31st, 2022
  • Pandemic Fraud: Fauci Pushed US to Spend $1.5 Billion on Big Pharma Drug That Has No Proven Benefits
    Pandemic Fraud: Fauci Pushed US to Spend $1.5 Billion on Big Pharma Drug That Has No Proven BenefitsJuly 24th, 2021
  • Covid-19: Lopinavir-Ritonavir Combo Falls Short—Again
    Covid-19: Lopinavir-Ritonavir Combo Falls Short—AgainOctober 7th, 2020
  • Join now to see all

Grant Support

  • Intravenous Zanamir In Experimental InfluenzaNational Center For Research Resources1998–1999
  • Rimantadine In Treating Influenza A Virus In Adult PatientsNational Center For Research Resources1989
  • Prophylactic Efficacy Of Interferon-Beta 17 Serine In Naturally Acquired ColdsNational Center For Research Resources1988–1989
  • Multiple Dose Pharmacokinetics Of Rimantadine In Older VolunteersNational Center For Research Resources1987–1988

Dr. Frederick Hayden, Dr. Frederick Hayden, MD, Dr. F Hayden, Dr. Frederick G. Hayden